Allogene Therapeutics, Inc.
ALLO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737287
In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Allogene Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 192 | 3 | 168 | −21 |
| Shares | 106.3M | 260.6K | 111.5M | +5.48M (+5.2%) |
| Value | $1.15B | $2.81M | $700.9M | −$443.4M (−38.7%) |
3 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held Allogene Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 440,100 | $2.77M | 0.00% |
| Kynam Capital Management, LP | 396,378 | $2.49M | 0.38% |
| AXA S.A. | 337,400 | $2.12M | 0.01% |
| Susquehanna Fundamental Investments, LLC | 195,309 | $1.23M | 0.02% |
| Schroder Investment Management Group | 190,699 | $1.20M | 0.00% |
| Trexquant Investment LP | 111,885 | $703.8K | 0.02% |
| Axq Capital, LP | 73,052 | $459.5K | 0.32% |
| Point72 Middle East FZE | 56,220 | $353.6K | 0.03% |
| NinePointTwo Capital | 27,343 | $171.0K | 0.07% |
| Callan Capital, LLC | 19,224 | $120.9K | 0.01% |
| Alpine Global Management, LLC | 18,267 | $115.0K | 0.04% |
| Inceptionr LLC | 16,488 | $103.7K | 0.05% |
| Caption Management, LLC | 15,000 | $94.3K | 0.02% |
| Pictet Asset Management SA | 10,480 | $66.0K | 0.00% |
| Nordwand Advisors, LLC | 9,528 | $59.9K | 0.01% |
| Lazard Asset Management LLC | 2,910 | $17.0K | 0.00% |
| Group One Trading, L.P. | 288 | $1.81K | 0.00% |
| Advisory Services Network, LLC | 148 | $931 | 0.00% |
| Dark Forest Capital Management LP | 39 | $245 | 0.00% |
| Steward Financial Group LLC | 7 | $0 | 0.00% |
Sold out (41)
Institutions that held Allogene Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
Not filed for Q4 2022 yet (3)
Institutions that held Allogene Therapeutics, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Eaton Vance Management | 237,155 | $2.56M |
| Shikiar Asset Management Inc | 23,250 | $251.0K |
| Wipfli Financial Advisors LLC, | 243 | $3.00K |